Lucknow: The unintentional mingling of the Covid-19 vaccine in the Siddharthnagar district now formed the country’s policy on a vaccine cocktail.
In May 2021, A total of 18 residents of the village of Audhai Kalan were given a covishield at the Badhni Primary Health Center in the first week of April, but on May 14 they were given Covaxin as a second dose of the guidelines.
Later, 16 of these beneficiaries were included in the Indian Medical Research Council called ‘Serendipitous Covid-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of the Heterogian regime’.
The initial findings of this study have been distributed in Medrxiv, free online archives and distribution servers, and are ready for peer reviews.
This study shows that immunization with a combination is not only safe but also causes better immunogenicity.
This research includes 40 people divided into three categories.
While accidental receivers are placed in the heterogeneous group (covishield + covaxin), the other two are homogeneous groups (covishield + covishield and covaxin + covaxin).
The groups witnessed and evaluated after nine weeks for immunogenicity – immunity to viruses – and reactogenicity, the term used to describe side effects after administration of vaccines.
ICMR work was coordinated by the regional medical research center at Gorakhpur.
Rajni Kant’s director said: “Overall, this study shows that immunization with a combination of heterologists from Covishield and Covaxin are safe and bring up immunogenicity better than two doses of homologous vaccination using the same vaccine.” “It is also noted that immunity to different strains, Beta and Delta variants are superior in the heterologist group.
However, multicentre random control trials need to be done to prove convincingly,” he added.
These findings have important implications for Covid-19 vaccination because heterogic immunization can cause better protection against the SARS-COV-2 variant strain, said Dr Kant.
“The mixed regimen will also help overcome the challenges of vaccine shortages in India where the large population must be vaccinated,” he added.
But experts are views that it is too early to celebrate findings.
“The main findings have not been reviewed, and the patient will be evaluated several times before the final conclusion can be withdrawn.
However, they must promise,” said a senior researcher at ICMR.
‘Mixing coincidence the vaccine above can change useful’
